AstraZeneca to Delist from Nasdaq, Transition to NYSE

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Jan 20 2026

0mins

Source: Benzinga

AstraZeneca's stock fell 5.01% as it crossed below the 20-day SMA amid broader market declines, with the Nasdaq-100 down 1.53% and the S&P 500 down 1.33%.

The company announced its voluntary withdrawal from Nasdaq, with trading for its American Depositary Shares ceasing on January 30, 2026. This strategic shift aims to enhance its global market presence by directly listing on the NYSE starting February 2, 2026, which is expected to provide a unified listing structure for global investors and improve market visibility.

This transition reflects AstraZeneca's strategy to align its trading platforms and enhance its appeal to investors, particularly in the U.S. market, while also indicating a reassessment of its future strategy in light of market dynamics.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free